Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Drug Profile

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Alternative Names: IM19 CAR-T cells; IM19-CAR-T-Cells-Beijing-Immunochina-Medical-Science-and-Technology; IM19CAR-T; IM19CAR-T-Beijing-Immunochina-Medical-Science-and-Technology

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Leukaemia
  • Phase I/II Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 09 Dec 2023 Phase-I/II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater) (Parenteral) before December 2023 (NCT05155215)
  • 09 Dec 2023 Efficacy data from a phase I/II trial in Mantle cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 01 Dec 2023 Phase-I clinical trials in Mantle-cell lymphoma in China (Parenteral) prior to December 2023 (Beijing Immunochina Medical Science and Technology pipeline, December 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top